Case histories / Thromboserin

Thromboserin

Thromboserin

Supporting a biotechnology company dedicated to advancing the treatment of thrombotic diseases, particularly in the areas of blood clotting and related disorders.

Working from poor quality hard copy source materials, Niche rescued and rebuilt Thromboserin's Investigator's Brochure for TH001, laying the regulatory foundation for their anti-thrombotic clinical programme.

01 Summary

Thromboserin Ltd. is an ‘innovator’ research company and their mission is to focus primarily on preventing arterial thrombosis. TH001 was granted a US Patent in December 2015, giving them IP until 2030.

  • Thromboserin used Niche's expertise in writing of IBs and previous experience in the therapy area to quickly and efficiently develop the high-quality regulatory documents
  • The Niche team was actively involved in guiding regulatory strategy and meeting delivery timelines

 

02 Project background

Thromboserin is a biotechnology company dedicated to advancing the treatment of thrombotic diseases, particularly in the areas of blood clotting and related disorders. The company specialises in developing innovative therapies that aim to improve patient outcomes by addressing the underlying causes of thrombosis. With a strong focus on research and scientific discovery, Thromboserin is committed to pioneering new solutions that provide safer, more effective alternatives to current treatment options. Through its cutting-edge research, the company strives to make a meaningful impact on the global fight against thrombosis and related diseases.

03 Delivery

Thromboserin first approached Niche to create the Investigator's Brochure (IB) for their product, TH001. This was particularly challenging as the information provided by the original Sponsor was poor quality and in hard copy only. Niche's renowned expertise in the writing of IBs ensured the quick and effective delivery of this document which was used to inform Thromboserin’s Protocol and subsequently used to build their Clinical Trial Application. Niche also aided Thromboserin’s search for development partners to support the company in their clinical development.

“

We have always been impressed by the standard of the work delivered by the Niche team. In addition, the contracting process is simple and efficient, communication is open, frequent and proactive, with any issues getting resolved quickly and efficiently.

Professor Mark NobleThromboserin ★★★★★

Facing a similar challenge?

Tell us where your programme is. We will show you how we can help.

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility